These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36658041)

  • 1. Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.
    Allaire NE; Griesenbach U; Kerem B; Lueck JD; Stanleigh N; Oren YS
    J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S39-S44. PubMed ID: 36658041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
    Egan ME
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?
    Oliver KE; Carlon MS; Pedemonte N; Lopes-Pacheco M
    Expert Opin Pharmacother; 2023; 24(14):1545-1565. PubMed ID: 37379072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging medicines to improve the basic defect in cystic fibrosis.
    Fajac I; Sermet-Gaudelus I
    Expert Opin Emerg Drugs; 2022 Sep; 27(3):229-239. PubMed ID: 35731915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.
    Kim YJ; Krainer AR
    Mol Cells; 2023 Jan; 46(1):10-20. PubMed ID: 36697233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
    Ensinck MM; Carlon MS
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state of CFTR modulators for treatment of Cystic Fibrosis.
    Despotes KA; Donaldson SH
    Curr Opin Pharmacol; 2022 Aug; 65():102239. PubMed ID: 35609385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CFTR RNA- and DNA-based therapies.
    Harrison PT
    Curr Opin Pharmacol; 2022 Aug; 65():102247. PubMed ID: 35709547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators.
    Fajac I; Sermet I
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators.
    Burke A; Thomson RM; Wainwright CE; Bell SC
    Semin Respir Crit Care Med; 2023 Apr; 44(2):287-296. PubMed ID: 36649736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
    Carbone A; Vitullo P; Di Gioia S; Conese M
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
    Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
    Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.